scholarly journals Gasto farmacéutico en diabetes mellitus en una región de España según el Clinical Risk Group, 2012

2016 ◽  
Vol 15 (30) ◽  
Author(s):  
Luis Alvis Estrada ◽  
David Vivas-Consuelo ◽  
Vicent Caballer-Tarazona ◽  
Ruth Usó-Talamantes ◽  
Carla Sancho-Mestre ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Group ◽  
Risk Groups ◽  
Clinical Risk ◽  
Clinical Risk Groups

<p>Se pretende estimar la multimorbilidad asociada con diabetes mellitus tipo 2 y su relación con el gasto farmacéutico, para lo cual se realizó un estudio de corte transversal durante el año 2012. Se identificó a 350 015 individuos diabéticos, a través de códigos clínicos, usando la Clasificación Internacional de Enfermedades y el software 3M Clinical Risk Groups. Todos los pacientes fueron clasificados en cuatro grupos de morbilidad. El primer grupo corresponde al estadio inicial, el segundo grupo incluye el núcleo de multimorbilidad de pacientes en fases intermedia y avanzada, el tercer grupo incluye pacientes con diabetes y enfermedades malignas, y el último grupo es de pacientes en estado catastrófico, principalmente enfermos renales crónicos. La prevalencia bruta de diabetes fue de 6,7 %. El gasto promedio total fue de € 1257,1. La diabetes se caracteriza por una fuerte presencia de otras condiciones crónicas y tiene un gran impacto en el gasto farmacéutico.</p>

scholarly journals Age dependence of modern clinical risk groups for localized prostate cancer – a population-based study

2019 ◽  
Author(s):  
Minh-Phuong Huynh-Le ◽  
Tor Åge Myklebust ◽  
Christine H. Feng ◽  
Roshan Karunamuni ◽  
Tom Børge Johannesen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Gleason Score ◽  
Risk Group ◽  
Risk Groups ◽  
Low Risk ◽  
Intermediate Risk ◽  
Clinical Risk ◽  
High Risk Disease ◽  
Clinical Risk Groups

AbstractBackgroundOptimal prostate cancer (PCa) screening strategies will focus on men most likely to have potentially-lethal, localized disease. Age-specific incidence rates (ASIRs) for clinical risk groups could guide risk-stratified screening.ObjectiveDetermine ASIRs and proportions of PCa diagnoses in Norway for modern risk-group and Gleason score categories.Design, Setting, and ParticipantsAll men diagnosed with PCa in Norway in 2014-2017 (n=20,356).Outcome Measurements and Statistical AnalysisPatients were assigned to clinical risk groups: low, favorable-intermediate, unfavorable-intermediate, high, regional, and metastatic, using Gleason score and clinical stage. Associations were assessed between age and (1) Gleason score (including Gleason 3+4 and 4+3) and (2) PCa risk group. Risk-group ASIRs were calculated by multiplying the overall Norwegian ASIR by the proportions observed for each category.ResultsOlder age was significantly associated with higher Gleason score and more advanced disease. For example, among men aged 55-59, 65-69, 75-79, and 85-89 years, the percentage with Gleason 8-10 disease was 16.5%, 23.4%, 37.2%, and 59.9%, respectively (p<0.001); the percentage with at least high-risk disease was 29.3%, 39.1%, 60.4%, and 90.6%, respectively. Corresponding percentages for low-risk PCa were 24.0%, 17.9%, 10.2%, and 4.1% (p<0.001). The respective maximum ASIRs (per 100,000 men) for low-risk, favorable-intermediate-risk, unfavorable-intermediate-risk, high-risk, regional, and metastatic disease were: 157.1, 183.8, 194.8, 408.3, 172.3, and 330.0; incidence for low-risk and favorable-intermediate-risk PCa peaked before age 70, while more advanced categories peaked after 70. At age 75-79 years, the ASIR of high-risk disease was approximately 6 times greater than at 55-59 years.ConclusionsRisk of clinically-significant, localized PCa increases with age. Healthy older men may be among those most likely to benefit from PCa screening.

scholarly journals Pharmaceutical Cost Analysis of Diabetes Mellitus Using Clinical Risk Groups in Valencian Community

2013 ◽  
Vol 16 (7) ◽  
pp. A691
Author(s):  
M. Romero ◽  
R. Uso Talamantes ◽  
D. Vivas Consuelo ◽  
E. De la Poza Plaza ◽  
C. Sancho Mestre ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Cost Analysis ◽  
Risk Groups ◽  
Clinical Risk ◽  
Pharmaceutical Cost ◽  
Clinical Risk Groups

scholarly journals Age Dependence of Prostate Cancer Clinical Risk Groups

2019 ◽  
Vol 105 (1) ◽  
pp. E275
Author(s):  
C.H. Feng ◽  
M.P. Huynh-Le ◽  
T.Å. Myklebust ◽  
T.B. Johannesen ◽  
A.M. Dale ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Groups ◽  
Age Dependence ◽  
Clinical Risk ◽  
Clinical Risk Groups

scholarly journals Immunosurveillance of childhood ALL: polymorphic interferon-γ alleles are associated with age at diagnosis and clinical risk groups

Leukemia ◽  
2004 ◽  
Vol 19 (1) ◽  
pp. 44-48 ◽  
Author(s):  
T Cloppenborg ◽  
M Stanulla ◽  
M Zimmermann ◽  
M Schrappe ◽  
K Welte ◽  
...  
Keyword(s):  
Risk Groups ◽  
Interferon Γ ◽  
Age At Diagnosis ◽  
Childhood All ◽  
Clinical Risk ◽  
Clinical Risk Groups

scholarly journals Cost-effectiveness of paediatric influenza vaccination in the Netherlands

2020 ◽  
Author(s):  
Pieter T. de Boer ◽  
Franklin C.K. Dolk ◽  
Lisa Nagy ◽  
Jan C. Wilschut ◽  
Richard Pitman ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cost Saving ◽  
Influenza Vaccination ◽  
Vaccination Programme ◽  
Risk Groups ◽  
Inactivated Vaccine ◽  
Vaccination Strategies ◽  
Clinical Risk ◽  
Vaccine Type ◽  
Clinical Risk Groups

AbstractBackgroundThis study evaluates the cost-effectiveness of extending the Dutch influenza vaccination programme for elderly and clinical risk groups to include paediatric influenza vaccination, taking indirect protection into account.MethodsAn age-structured dynamic transmission model was used that was calibrated to influenza-associated GP visits over four seasons (2010/11 to 2013/14). The clinical and economic impact of different paediatric vaccination strategies were compared over 20 years, varying the targeted age range, the vaccine type for children and the vaccine type for elderly and clinical risk groups. Outcome measures include averted symptomatic infections and deaths, societal costs and quality-adjusted life years (QALYs), incremental cost-effectiveness ratios, and net health benefits (NHBs), using a willingness-to-pay threshold of €20,000 per QALY gained.ResultsAt an assumed coverage of 50%, adding vaccination of 2- to 17-year-olds with quadrivalent-live-attenuated influenza vaccine (Q-LAIV) to the current influenza vaccination programme was estimated to avert on average 406,270 symptomatic cases and 83 deaths per season compared to vaccination of elderly and risk groups with trivalent inactivated vaccine (TIV), and was cost-saving (cumulative 20-year savings of 36,396 QALYs and €1,680 million; NHB: 120,411 QALYs). This strategy dominated paediatric vaccination strategies targeting 2- to 6-year-olds or 2- to 12-year-olds, or paediatric vaccination strategies with TIV. The highest NHB was obtained when 2- to 17-year-olds were vaccinated with Q-LAIV and existing target groups switched from TIV to quadrivalent inactivated vaccine (NHB: 132,907 QALYs).ConclusionModelling indicates that paediatric influenza vaccination reduces the disease burden of influenza substantially and is cost-saving.

scholarly journals Predictability of pharmaceutical spending in primary health services using Clinical Risk Groups

Health Policy ◽  
2014 ◽  
Vol 116 (2-3) ◽  
pp. 188-195 ◽  
Author(s):  
David Vivas-Consuelo ◽  
Ruth Usó-Talamantes ◽  
José Luis Trillo-Mata ◽  
Maria Caballer-Tarazona ◽  
Isabel Barrachina-Martínez ◽  
...  
Keyword(s):  
Health Services ◽  
Risk Groups ◽  
Clinical Risk ◽  
Primary Health ◽  
Clinical Risk Groups ◽  
Pharmaceutical Spending ◽  
Primary Health Services

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

2012 ◽  
Vol 30 (13) ◽  
pp. 1422-1428 ◽  
Author(s):  
Henk Visscher ◽  
Colin J.D. Ross ◽  
S. Rod Rassekh ◽  
Amina Barhdadi ◽  
Marie-Pierre Dubé ◽  
...  
Keyword(s):  
Risk Factors ◽  
High Risk ◽  
Genetic Variants ◽  
Risk Group ◽  
Treatment Options ◽  
Risk Groups ◽  
High Risk Group ◽  
Clinical Risk Factors ◽  
Nucleotide Polymorphisms ◽  
Clinical Risk

Purpose Anthracycline-induced cardiotoxicity (ACT) is a serious adverse drug reaction limiting anthracycline use and causing substantial morbidity and mortality. Our aim was to identify genetic variants associated with ACT in patients treated for childhood cancer. Patients and Methods We carried out a study of 2,977 single-nucleotide polymorphisms (SNPs) in 220 key drug biotransformation genes in a discovery cohort of 156 anthracycline-treated children from British Columbia, with replication in a second cohort of 188 children from across Canada and further replication of the top SNP in a third cohort of 96 patients from Amsterdam, the Netherlands. Results We identified a highly significant association of a synonymous coding variant rs7853758 (L461L) within the SLC28A3 gene with ACT (odds ratio, 0.35; P = 1.8 × 10−5 for all cohorts combined). Additional associations (P < .01) with risk and protective variants in other genes including SLC28A1 and several adenosine triphosphate–binding cassette transporters (ABCB1, ABCB4, and ABCC1) were present. We further explored combining multiple variants into a single-prediction model together with clinical risk factors and classification of patients into three risk groups. In the high-risk group, 75% of patients were accurately predicted to develop ACT, with 36% developing this within the first year alone, whereas in the low-risk group, 96% of patients were accurately predicted not to develop ACT. Conclusion We have identified multiple genetic variants in SLC28A3 and other genes associated with ACT. Combined with clinical risk factors, genetic risk profiling might be used to identify high-risk patients who can then be provided with safer treatment options.

scholarly journals Relación entre la calidad de vida de los pacientes, mediante el cuestionario EuroQol-5D, y la clasificación de morbilidad Clinical Risk Groups

2015 ◽  
Vol 4 (2) ◽  
pp. 47-52
Author(s):  
Daniel Ríos García ◽  
Meritxell Calderó Solé ◽  
Manuel Pena Arnaiz ◽  
Virginia Sánchez Fernández ◽  
Jordi Real Gatius ◽  
...  
Keyword(s):  
Risk Groups ◽  
Clinical Risk ◽  
Calidad De Vida ◽  
Clinical Risk Groups ◽  
Euroqol 5D
Sign in / Sign up

Export Citation Format

Share Document